Rchr
J-GLOBAL ID:200901094758615874   Update date: Apr. 04, 2024

Matsumura Takayuki

マツムラ タカユキ | Matsumura Takayuki
Affiliation and department:
Job title: Chief
Homepage URL  (1): https://www.niid.go.jp/niid/ja/from-imm/937-imm-02.html
Research field  (2): Infectious disease ,  Pharmaceuticals - health and biochemistry
Research keywords  (2): Vaccine ,  Innate immunity
Research theme for competitive and other funds  (26):
  • 2024 - 2028 劇症型溶血性レンサ球菌感染症における炎症収束・修復機構の解析
  • 2023 - 2025 迅速な中和抗体誘導を可能にするRNAワクチンモダリティの研究開発
  • 2022 - 2025 細菌による希少感染症の治療・予防・診断の基盤強化に資する研究 (分担)
  • 2022 - 2025 B型慢性肝炎の機能的治癒を目指した新たな免疫治療開発に資する研究 (分担)
  • 2022 - 2025 新規モダリティワクチン製剤に対する有効性・安全性評価法開発に資する免疫学的研究
Show all
Papers (44):
  • Eriko Morino, Sohtaro Mine, Noriko Tomita, Yukari Uemura, Yosuke Shimizu, Sho Saito, Tetsuya Suzuki, Nobumasa Okumura, Haruka Iwasaki, Junko Terada, et al. Mpox Neutralizing Antibody Response to LC16m8 Vaccine in Healthy Adults. NEJM evidence. 2024. 3. 3. EVIDoa2300290
  • Taishi Onodera, Nicolas Sax, Takashi Sato, Yu Adachi, Ryutaro Kotaki, Takeshi Inoue, Ryo Shinnakasu, Takayuki Nakagawa, Shuetsu Fukushi, Tommy Terooatea, et al. CD62L expression marks SARS-CoV-2 memory B cell subset with preference for neutralizing epitopes. Science advances. 2023. 9. 24. eadf0661
  • Eita Sasaki, Hideki Asanuma, Haruka Momose, Keiko Furuhata, Takuo Mizukami, Takayuki Matsumura, Yoshimasa Takahashi, Isao Hamaguchi. Systemically inoculated adjuvants stimulate pDC-dependent IgA response in local site. Mucosal immunology. 2023
  • Tomohiro Takano, Takashi Sato, Ryutaro Kotaki, Saya Moriyama, Shuetsu Fukushi, Masahiro Shinoda, Kiyomi Kabasawa, Nagashige Shimada, Mio Kousaka, Yu Adachi, et al. Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain. Nature communications. 2023. 14. 1. 1451-1451
  • Yukie Kashima, Taketoshi Mizutani, Kaori Nakayama-Hosoya, Saya Moriyama, Takayuki Matsumura, Yoshihiro Yoshimura, Hiroaki Sasaki, Hiroshi Horiuchi, Nobuyuki Miyata, Kazuhito Miyazaki, et al. Multimodal single-cell analyses of peripheral blood mononuclear cells of COVID-19 patients in Japan. Scientific reports. 2023. 13. 1. 1935-1935
more...
MISC (21):
  • 松村隆之, 高橋宜聖. COVID-19ワクチンの現状と今後の動向. Medical Technology. 2022. 50. 4. 417-421
  • 本田 尚子, 佐藤 法仁, 中山 真彰, 松村 隆之, 関塚 剛史, 黒田 誠, 阿戸 学, 小林 和夫, 石井 孝司, 大原 直也. 16S rRNA遺伝子の513シトシン挿入変異を有するストレプトマイシン依存性Mycobacterium bovis BCG株(Streptomycin dependent Mycobacterium bovis BCG possessing a 513 cytosine insertion in 16S rRNA gene). 日本細菌学雑誌. 2022. 77. 1. 112-112
  • 松村隆之, 五十川正記, 高橋宜聖. COVID-19と宿主免疫応答. 病理と臨床. 2021. 39. 12. 1190-1198
  • 五十川 正記, 松村 隆之, 高橋 宜聖. COVID-19における自然免疫と獲得免疫. 呼吸器内科. 2021. 40. 4. 427-431
  • 本田 尚子, 佐藤 法仁, 中山 真彰, 松村 隆之, 関塚 剛史, 黒田 誠, 阿戸 学, 小林 和夫, 石井 孝司, 大原 直也. 16S rRNA遺伝子の513シトシン挿入変異を有するストレプトマイシン依存性Mycobacterium bovis BCG株(Streptomycin dependent Mycobacterium bovis BCG possessing a 513 cytosine insertion in 16S rRNA gene). 日本細菌学雑誌. 2020. 75. 1. 154-154
more...
Patents (2):
  • フラビウイルス交差中和抗体及び医薬組成物
  • 抗体並びに劇症型溶血性レンサ球菌感染症を予防及び/又は治療するための薬剤
Professional career (1):
  • Ph. D.
Work history (16):
  • 2023/09 - 現在 National Institute of Infectious Diseases
  • 2021/04 - 現在 National Institute of Infectious Diseases Laboratory of Innate Immunity, Research Center for Drug and Vaccine Development Chief
  • 2019/08 - 2021/03 National Institute of Infectious Diseases Laboratory of Bacterial Infection and Immunity, Department of Immunology Chief
  • 2013/08 - 2019/07 National Institute of Infectious Diseases Laboratory of Bacterial Infection and Immunity, Department of Immunology Senior Researcher
  • 2015/09 - 2017/03 Niigata University Faculty of Medicine
Show all
Awards (1):
  • 2012/04 - Tadamitsu Kishimoto International Travel Award
Association Membership(s) (4):
JAPANESE SOCIETY FOR BACTERIOLOGY ,  THE JAPANESE SOCIETY FOR IMMUNOLOGY ,  THE JAPANESE SOCIETY FOR VACCINOLOGY ,  THE JAPANESE ASSOCIATION FOR INFECTIOUS DISEASES
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page